• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconsanofi

sanofi

Page 3 of 6
In this photo illustration various medical syringes seen with Sanofi Pasteur company logo displayed on a screen in the background.
HealthGSK and Sanofi shares fall as the pharma giants delay COVID-19 vaccine until late 2021
By David MeyerDecember 11, 2020
For AstraZeneca’s COVID vaccine, less may be more—and that’s puzzling researchers
HealthFor AstraZeneca’s COVID vaccine, less may be more—and that’s puzzling researchers
By Angelica LaVito, John Lauerman and BloombergNovember 25, 2020
AstraZeneca-Oxford COVID vaccine on track for year end, CEO Pascal Soriot says
HealthAstraZeneca-Oxford COVID vaccine on track for year end, CEO Pascal Soriot says
By Suzi Ring, James Paton and BloombergNovember 5, 2020
Leadership Next podcast with Sanofi CEO Paul Hudson.
LeadershipSanofi CEO sees Big Pharma collaborating more even after a COVID vaccine is approved
By McKenna MooreOctober 27, 2020
Medical syringe is seen with 'covid-19' sign displayed on a screen in the background in this illustration photo taken in Poland on October 12, 2020.
HealthAs COVID-19 numbers boom and markets tank, Europe’s leaders urge vaccine coordination
By David MeyerOctober 15, 2020
Investors send global stocks higher on vaccine hopes and stimulus goodies—but tech shares continue to lag
NewslettersInvestors send global stocks higher on vaccine hopes and stimulus goodies—but tech shares continue to lag
By Bernhard WarnerSeptember 3, 2020
Sanofi, GlaxoSmithKline reach multi-billion dollar deal with U.S. for coronavirus vaccine
NewslettersSanofi, GlaxoSmithKline reach multi-billion dollar deal with U.S. for coronavirus vaccine
By Sy MukherjeeJuly 31, 2020
U.S. pledges $2.1 billion for up to 600 million doses of Sanofi, GlaxoSmithKline vaccine
HealthU.S. pledges $2.1 billion for up to 600 million doses of Sanofi, GlaxoSmithKline vaccine
By James Paton and BloombergJuly 31, 2020
France’s Sanofi to sell stake in high-flying Regeneron to fund new drugs discoveries
FinanceFrance’s Sanofi to sell stake in high-flying Regeneron to fund new drugs discoveries
By James Paton, Riley Griffin and BloombergMay 26, 2020
British pharma giant AstraZeneca get $1 billion from the U.S. to make coronavirus vaccine
HealthBritish pharma giant AstraZeneca get $1 billion from the U.S. to make coronavirus vaccine
By John Lauerman and BloombergMay 21, 2020
Will COVID-19 change how Big Pharma does clinical trials?
MagazineWill COVID-19 change how Big Pharma does clinical trials?
By Erika FryMay 15, 2020
‘Unacceptable:’ A new France-U.S. spat erupts over Sanofi’s coronavirus vaccine plans
Health‘Unacceptable:’ A new France-U.S. spat erupts over Sanofi’s coronavirus vaccine plans
By Phil Serafino and BloombergMay 14, 2020
Sanofi will combine its experimental coronavirus vaccine with GlaxoSmithKline Plc’s adjuvant technology, which may allow more doses of a shot to be produced.
HealthSanofi and GlaxoSmithKline are teaming up to develop a coronavirus vaccine
By James Paton, Suzi Ring and BloombergApril 14, 2020
Paul Hudson, chief executive officer of Sanofi, gestures as he speaks during a panel session on the sidelines of the China International Import Expo (CIIE) in Shanghai, China, on Tuesday, Nov. 5, 2019. The CIIE -- now in its second year -- is designed to showcase the countrys desire to shift its economy toward consumption by buying more foreign goods. Photographer: Qilai Shen/Bloomberg via Getty Images
NewslettersBig pharma’s big chance
By Katherine Dunn and Alan MurrayApril 3, 2020
Sanofi CEO Paul Hudson
NewslettersCoronavirus interruption of drug supply chain pushes Sanofi to open a firm in France
By Sy MukherjeeFebruary 24, 2020
1
  • 1
  • 2
  • 3
  • 4
  • 5
6
Most Popular
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250placeholder alt text
By Fortune EditorsApril 9, 2026
Investing
Mark Cuban admits he made a mistake letting go of the Mavericks: 'I don't regret selling. I regret who I sold to'placeholder alt text
By Fortune EditorsApril 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.